Citations

Showing 10 of 108083 citations.

Smartphone photography utilized to measure wrist range of motion
Wagner, Eric R. , Mica, Megan Conti , Wagner, Eric R , Shin, Alexander Y.

Mayo Clinic

Journal of Hand Surgery (European Volume) | September 5, 2017 | Volume: 43 | Issue: 2 | Pages: 187-192

10.1177/1753193417729140 | PMID 28872411 Get It

The purpose was to determine if smartphone photography is a reliable tool in measuring wrist movement. Smartphones were used to take digital photos of both wrists in 32 normal participants (64 wrists) at extremes of wrist motion. The smartphone measurements were compared with clinical goniometry measurements. There was a very high correlation between the clinical goniometry and smartphone measurements, as the concordance coefficients were high for radial deviation, ulnar deviation, wrist extension and wrist flexion. The Pearson coefficients also demonstrated the high precision of the smartphone measurements. The Bland–Altman plots demonstrated 29–31 of 32 smartphone measurements were within the 95% confidence interval of the clinical measurements for all positions of the wrists. There was high reliability between the photography taken by the volunteer and researcher, as well as high inter-observer reliability. Smartphone digital photography is a reliable and accurate tool for measuring wrist range of motion. Level of evidence: II
Silicone Oil–Induced Nasal Polyposis: A Case Report
Patel, Vishal S. , Hwang, Peter H. , Kossler, Andrea L. , Choby, Garret

Mayo Clinic

Otolaryngology–Head and Neck Surgery | September 5, 2017 | Volume: 157 | Issue: 5 | Pages: 903-904

10.1177/0194599817728896 | PMID 28871877 Get It

Perioperative Management of Beta Blockers and Other Antiarrhythmic Medications
Irizarry-Alvarado, Joan M.

Mayo Clinic

Current Clinical Pharmacology | September 5, 2017 | Volume: 12 | Issue: 3 | Pages: 141-144

10.2174/1574884712666170829114820 | PMID 28847276 Get It

Relating gastric scintigraphy and symptoms to motility capsule transit and pressure findings in suspected gastroparesis
Hasler, William L. , May, Kevin P. , Wilson, Laura , Natta, Mark L. Van , Parkman, Henry P. , Pasricha, Pankaj J. , Koch, Kenneth L. , Abell, Thomas L. , McCallum, Richard W. , Snape, William J., Sarosiek, Irene , Farrugia, Gianrico , Calles-Escandón, Jorge, Grover, Madhusudan , Tonascia, James , Lee, L. A., Miriel, Laura , Hamilton, Frank A., Hasler, W L , Parkman, H P , Abell, T L , Nguyen, Linda Anh B. , Clarke, John O.

Mayo Clinic

Neurogastroenterology & Motility | September 5, 2017 | Volume: 30 | Issue: 2 | Pages: No page available

10.1111/nmo.13196 | PMID 28872760 Get It

Abstract Background Wireless motility capsule ( WMC ) findings are incompletely defined in suspected gastroparesis. We aimed to characterize regional WMC transit and contractility in relation to scintigraphy, etiology, and symptoms in patients undergoing gastric emptying testing. Methods A total of 209 patients with gastroparesis symptoms at NIDDK Gastroparesis Consortium centers underwent gastric scintigraphy and WMC s on separate days to measure regional transit and contractility. Validated questionnaires quantified symptoms. Key Results Solid scintigraphy and liquid scintigraphy were delayed in 68.8% and 34.8% of patients; WMC gastric emptying times ( GET ) were delayed in 40.3% and showed 52.8% agreement with scintigraphy; 15.5% and 33.5% had delayed small bowel ( SBTT ) and colon transit ( CTT ) times. Transit was delayed in ≥2 regions in 23.3%. Rapid transit was rarely observed. Diabetics had slower GET but more rapid SBTT versus idiopathics ( P ≤ .02). GET delays related to greater scintigraphic retention, slower SBTT , and fewer gastric contractions ( P ≤ .04). Overall gastroparesis symptoms and nausea/vomiting, early satiety/fullness, bloating/distention, and upper abdominal pain subscores showed no relation to WMC transit. Upper and lower abdominal pain scores ( P ≤ .03) were greater with increased colon contractions. Constipation correlated with slower CTT and higher colon contractions ( P = .03). Diarrhea scores were higher with delayed SBTT and CTT ( P ≤ .04). Conclusions & Inferences Wireless motility capsules define gastric emptying delays similar but not identical to scintigraphy that are more severe in diabetics and relate to reduced gastric contractility. Extragastric transit delays occur in >40% with suspected gastroparesis. Gastroparesis symptoms show little association with WMC profiles, although lower symptoms relate to small bowel or colon abnormalities.
Systematic review with meta‐analysis: the association between hepatitis E seroprevalence and haemodialysis
Haffar, Samir , Bazerbachi, Fateh , Leise, Michael D. , Albright, Robert C. , Murad, M. Hassan , Kamath, Patrick S. , Watt, Kymberly D. , Haffar, S , Bazerbachi, F , Murad, M Hassan , Dillon, John

Mayo Clinic

Alimentary Pharmacology & Therapeutics | September 4, 2017 | Volume: 46 | Issue: 9 | Pages: 790-799

10.1111/apt.14285 | PMID 28869287 Get It

SummaryBackgroundHepatitis E virus (HEV) infection appears to be more common than previously thought. HEV seroprevalence in patients on maintenance haemodialysis (HD) is unclear with a range from 0% to 44%. In addition, risk factors of transmission of HEV in patients on haemodialysis are unknown.AimTo perform a systematic review and meta‐analysis of HEV seroprevalence in HD patients compared with controls.MethodsA systematic search of several databases identified all observational studies with comparative arms. Two reviewers extracted data and assessed the methodological quality. A random‐effects model was used for pooled odds ratio (OR) and 95% confidence interval (CI) of positive anti‐HEV IgG in both groups. Heterogeneity and publication bias were assessed with appropriate tests.ResultsWe identified 31 studies from 17 countries between 1994 and 2016. Sixteen studies were judged to have adequate quality and 15 to have moderate limitations. HEV infection was more prevalent in patients on haemodialysis compared with controls (OR 2.47, 95% CI 1.79‐3.40, I2 = 75.2%, P < .01). We conducted several subgroup analyses without difference in results. Egger regression test did not suggest publication bias (P = .83). Specific risk factors of HEV transmission in patients on haemodialysis were not clearly identified.ConclusionsHepatitis E virus infection is more prevalent in patients on haemodialysis compared with non‐haemodialysis control groups. Further studies are needed to determine risk factors of acquisition, impact on health, and risk for chronic HEV especially among those patients going to receive organ transplantation.
Triheptanoin versus trioctanoin for long‐chain fatty acid oxidation disorders: a double blinded, randomized controlled trial
Gillingham, Melanie B. , Martin, Julie , Rose, Sarah, Goldstein, Amy , El‐Gharbawy, Areeg , DeWard, Stephanie J. , Lasarev, Michael , Pollaro, Jim, DeLany, James P. , Burchill, Luke J. , Shoemaker, James D. , Matern, Dietrich , Heitner, Stephen B. , Goodpaster, Bret H. , Harding, Cary O. , Vockley, Jerry , Burchill, Luke J , Gillingham, Melanie B

Mayo Clinic

Journal of Inherited Metabolic Disease | September 4, 2017 | Volume: 40 | Issue: 6 | Pages: 831-843

10.1007/s10545-017-0085-8 | PMID 28871440 Get It

AbstractBackgroundObservational reports suggest that supplementation that increases citric acid cycle intermediates via anaplerosis may have therapeutic advantages over traditional medium‐chain triglyceride (MCT) treatment of long‐chain fatty acid oxidation disorders (LC‐FAODs) but controlled trials have not been reported. The goal of our study was to compare the effects of triheptanoin (C7), an anaplerotic seven‐carbon fatty acid triglyceride, to trioctanoin (C8), an eight‐carbon fatty acid triglyceride, in patients with LC‐FAODs.MethodsA double blinded, randomized controlled trial of 32 subjects with LC‐FAODs (carnitine palmitoyltransferase‐2, very long‐chain acylCoA dehydrogenase, trifunctional protein or long‐chain 3‐hydroxy acylCoA dehydrogenase deficiencies) who were randomly assigned a diet containing 20% of their total daily energy from either C7 or C8 for 4 months was conducted. Primary outcomes included changes in total energy expenditure (TEE), cardiac function by echocardiogram, exercise tolerance, and phosphocreatine recovery following acute exercise. Secondary outcomes included body composition, blood biomarkers, and adverse events, including incidence of rhabdomyolysis.ResultsPatients in the C7 group increased left ventricular (LV) ejection fraction by 7.4% (p = 0.046) while experiencing a 20% (p = 0.041) decrease in LV wall mass on their resting echocardiogram. They also required a lower heart rate for the same amount of work during a moderate‐intensity exercise stress test when compared to patients taking C8. There was no difference in TEE, phosphocreatine recovery, body composition, incidence of rhabdomyolysis, or any secondary outcome measures between the groups.ConclusionsC7 improved LV ejection fraction and reduced LV mass at rest, as well as lowering heart rate during exercise among patients with LC‐FAODs.Clinical Trial Registration: Clinicaltrials.gov NCT01379625.
Using Naïve Bayesian Analysis to Determine Imaging Characteristics of KRAS Mutations in Metastatic Colon Cancer
Pershad, Yash , Govindan, Siddharth, Hara, Amy K., Bekaii‐Saab, Tanios , Wallace, Alex, Albadawi, Hassan , Öklü, Rahmi , Oklu, Rahmi , Bekaii-Saab, Tanios S , Borad, Mitesh J.

Mayo Clinic

Diagnostics | September 4, 2017 | Volume: 7 | Issue: 3 | Pages: 50

10.3390/diagnostics7030050 | PMID 28869500 Get It

Genotype, particularly Ras status, greatly affects prognosis and treatment of liver metastasis in colon cancer patients. This pilot aimed to apply word frequency analysis and a naive Bayes classifier on radiology reports to extract distinguishing imaging descriptors of wild-type colon cancer patients and those with v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations. In this institutional-review-board-approved study, we compiled a SNaPshot mutation analysis dataset from 457 colon adenocarcinoma patients. From this cohort of patients, we analyzed radiology reports of 299 patients (> 32,000 reports) who either were wild-type (147 patients) or had a KRAS (152 patients) mutation. Our algorithm determined word frequency within the wild-type and mutant radiology reports and used a naive Bayes classifier to determine the probability of a given word belonging to either group. The classifier determined that words with a greater than 50% chance of being in the KRAS mutation group and which had the highest absolute probability difference compared to the wild-type group included: “several”, “innumerable”, “confluent”, and “numerous” (p < 0.01). In contrast, words with a greater than 50% chance of being in the wild type group and with the highest absolute probability difference included: “few”, “discrete”, and “[no] recurrent” (p = 0.03). Words used in radiology reports, which have direct implications on disease course, tumor burden, and therapy, appear with differing frequency in patients with KRAS mutations versus wild-type colon adenocarcinoma. Moreover, likely characteristic imaging traits of mutant tumors make probabilistic word analysis useful in identifying unique characteristics and disease course, with applications ranging from radiology and pathology reports to clinical notes.
The Clinical Potential of Senolytic Drugs
Kirkland, James L. , Tchkonia, Tamar , Zhu, Yi , Niedernhofer, Laura J. , Tchkonia, Tamara, Tchkonia, T , Niedernhofer, Laura J , Robbins, Paul D. , Zhu, Yi

Mayo Clinic

Journal of the American Geriatrics Society | September 4, 2017 | Volume: 65 | Issue: 10 | Pages: 2297-2301

10.1111/jgs.14969 | PMID 28869295 Get It

Senolytic drugs are agents that selectively induce apoptosis of senescent cells. These cells accumulate in many tissues with aging and at sites of pathology in multiple chronic diseases. In studies in animals, targeting senescent cells using genetic or pharmacological approaches delays, prevents, or alleviates multiple age‐related phenotypes, chronic diseases, geriatric syndromes, and loss of physiological resilience. Among the chronic conditions successfully treated by depleting senescent cells in preclinical studies are frailty, cardiac dysfunction, vascular hyporeactivity and calcification, diabetes mellitus, liver steatosis, osteoporosis, vertebral disk degeneration, pulmonary fibrosis, and radiation‐induced damage. Senolytic agents are being tested in proof‐of‐concept clinical trials. To do so, new clinical trial paradigms for testing senolytics and other agents that target fundamental aging mechanisms are being developed, because use of long‐term endpoints such as lifespan or healthspan is not feasible. These strategies include testing effects on multimorbidity, accelerated aging‐like conditions, diseases with localized accumulation of senescent cells, potentially fatal diseases associated with senescent cell accumulation, age‐related loss of physiological resilience, and frailty. If senolytics or other interventions that target fundamental aging processes prove to be effective and safe in clinical trials, they could transform geriatric medicine by enabling prevention or treatment of multiple diseases and functional deficits in parallel, instead of one at a time.
Resting sympathetic activity is associated with the sympathetically mediated component of energy expenditure following a meal
Limberg, Jacqueline K. , Malterer, Katherine R., Matzek, Luke J. , Levine, James A. , Charkoudian, Nisha , Miles, John M. , Joyner, Michael J. , Curry, Timothy B. , Joyner, Michael J

Mayo Clinic

Physiological Reports | September 3, 2017 | Volume: 5 | Issue: 16 | Pages: e13389

10.14814/phy2.13389 | PMID 28867675 Get It

Molecular targeting of the Aurora-A/SMAD5 oncogenic axis restores chemosensitivity in human breast cancer cells
Gil, Małgorzata , Salisbury, Jeffrey L., Goetz, Mathew P., Haddad, Tufia C. , Iankov, Ianko, Kurokawa, Chenye B., Shumacher, Nicole, D’Assoro, Antonino B. , Suman, Vera, Degnim, Amy, Haddad, Tufia, Ingle, James N. , Galanis, Evanthia , D'Assoro, Antonino B, Opyrchal, Mateusz , Goetz, MP, Suman, Vera J. , Degnim, Amy C. , McCubrey, James Andrew

Mayo Clinic

Oncotarget | September 2, 2017 | Volume: 8 | Issue: 53 | Pages: 91803-91816

10.18632/oncotarget.20610 | PMID 29207686 Get It